Previous Close | 154.39 |
Open | 154.48 |
Bid | 150.47 x 100 |
Ask | 151.51 x 100 |
Day's Range | 149.34 - 154.50 |
52 Week Range | 143.52 - 218.88 |
Volume | |
Avg. Volume | 863,354 |
Market Cap | 18.996B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ALNY
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial. Full results of the Phase 2 KARDIA-2 trial, testing the twice-a-year injection zilebesiran, would be presented at the American College of Cardiology Annual Scientific Session in Atlanta on April 6, Roche said in a statement on Tuesday. In July last year, Roche agreed to develop and commercialise Alnylam’s zilebesiran to treat hypertension, the leading cause of cardiovascular disease worldwide.